{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:30:09Z","timestamp":1784716209096,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":2695,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.seizure.2005.11.005","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T14:07:22Z","timestamp":1137679642000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Pregabalin: A new antiepileptic drug for refractory epilepsy"],"prefix":"10.1016","volume":"15","author":[{"given":"Khalid","family":"Hamandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josemir W.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2005.11.005_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2005.11.005_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00019052-200404000-00015","article-title":"Clinical outcome of epilepsy surgery","volume":"17","author":"Polkey","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.seizure.2005.11.005_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/WNL.49.2.333","article-title":"Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs","volume":"49","author":"Walker","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.11.005_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(02)00106-7","article-title":"Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)","volume":"51","author":"Bialer","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2005.11.005_bib5","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.11.005_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.seizure.2005.11.005_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B","article-title":"3-substituted GABA analogs with central nervous system activity: a review","volume":"19","author":"Bryans","year":"1999","journal-title":"Med Res Rev"},{"key":"10.1016\/j.seizure.2005.11.005_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0703794","article-title":"Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity","volume":"132","author":"Field","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2005.11.005_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0022-3565(24)39009-3","article-title":"Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin","volume":"295","author":"Dooley","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2005.11.005_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","article-title":"Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex","volume":"42","author":"Fink","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2005.11.005_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/syn.10094","article-title":"Preferential action of gabapentin and pregabalin at P\/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices","volume":"45","author":"Dooley","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.seizure.2005.11.005_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","article-title":"Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C","volume":"105","author":"Fehrenbacher","year":"2003","journal-title":"Pain"},{"issue":"Suppl. 8","key":"10.1016\/j.seizure.2005.11.005_bib13","first-page":"35","article-title":"Profile of anticonvulsant activity of pregabalin in animal models","volume":"38","author":"Taylor","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl. 8","key":"10.1016\/j.seizure.2005.11.005_bib14","first-page":"29","article-title":"Comparison of S-(+)-3 isobutyl GABA (pregabalin) and gabapentin against kindled hippocampal seizures","volume":"38","author":"Williamson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.11.005_bib15","unstructured":"Lyrica\u00a9 Summary of product characteristics. Pfizer Ltd. 2004."},{"key":"10.1016\/j.seizure.2005.11.005_bib16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures","volume":"60","author":"French","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.11.005_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.11.005_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/01.WNL.0000150932.48688.BE","article-title":"Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy","volume":"64","author":"Beydoun","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.11.005_bib19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1528-1157.2001.44000.x","article-title":"Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin","volume":"42","author":"Huppertz","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.11.005_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1528-1157.1999.tb05561.x","article-title":"New antiepileptic drugs: comparison of key clinical trials","volume":"40","author":"Cramer","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.11.005_bib21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.291.5.605","article-title":"The new antiepileptic drugs: scientific review","volume":"291","author":"LaRoche","year":"2004","journal-title":"JAMA"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131105002232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131105002232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:34:21Z","timestamp":1761010461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131105002232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1059131105002232"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2005.11.005","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregabalin: A new antiepileptic drug for refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2005.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}